Researchers from Arvinas Inc. reported the preclinical characterization of bavdegalutamide (ARV-110), an androgen receptor (AR)-directed proteolysis targeting chimera (PROTAC) designed to selectively degrade wild-type AR and the majority of clinically relevant mutants of AR.
Gan & Lee Pharmaceuticals Co. Ltd. has synthesized antibody-drug conjugates comprising a monoclonal antibody covalently linked to exatecan derivatives through a linker reported to be useful for the treatment of cancer.
Haihe Biopharma Co. Ltd. has disclosed benzo(hetero)cycloalkyl compounds reported to be useful for the treatment of acne, spinal and bulbar muscular atrophy, and more.
Hervolution Therapeutics ApS (formerly Inprother Aps) has announced a $11.7 million series A financing to support its work developing novel human endogenous retrovirus (HERV)-targeted immunotherapies to address diseases of aging.
Engineered probiotics, mainly bacterial probiotics, are an emerging platform for in situ delivery of therapeutics, including anticancer therapies, to the gut. Writing in Cell Chemical Biology, researchers from Washington University School of Medicine and collaborators present a novel yeast-based therapeutic oral platform to deliver next-generation immune checkpoint inhibitor proteins directly to gastrointestinal tumors.
Biopolar Hongye (Nantong) Pharmaceutical Co., Ltd. has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon (CRBN) binding moiety covalently linked to a Bruton’s tyrosine kinase (BTK) binding moiety reported to be useful for the treatment of cancer, inflammatory and autoimmune diseases.
RSS
